| Naren Gursahaney
| Mr. Gursahaney, age 50, has been President of ADT Worldwide (now Tyco Security Solutions) since May 2007. Mr. Gursahaney joined Tyco in 2003 as Senior Vice President of Operational Excellence and became the President of Tyco Flow Control in January 2005 and President of the Tyco Engineered Products and Services segment in January 2006. Prior to joining Tyco, Mr. Gursahaney was the President and Chief Executive Officer of GE Medical Systems-Asia. During his ten year tenure at GE, Mr. Gursahaney held senior leadership positions in services, marketing and information management within the Medical Systems and Power Systems divisions and also worked at GE's corporate headquarters as the staff executive for the vice chairman and manager of business development. Prior to GE, Mr. Gursahaney spent four years with Booz Allen & Hamilton in Cleveland, Ohio and worked as an engineer for Westinghouse Electric Corporation in Baltimore, Maryland and Ashdod, Israel. |
| Mr John Adams
| Mr. Adams, age 59, served as managing director in the Financial Institutions Group at UBS Investment Bank, a financial services firm, from 2002 until 2013. Prior to joining UBS, Mr. Adams was with Credit Suisse’s Financial Institutions Group from 1985 until 2002. He currently serves on the board of directors of Navient Corporation, a loan management, servicing and asset recovery company. |
| Mr Michael Embler
| Michael J. Embler has served as a director of CIT since December 2009. He formerly served as the Chief Investment Officer of Franklin Mutual Advisers LLC, an asset management subsidiary of Franklin Resources, Inc. Mr. Embler joined Franklin Mutual Advisers in 2001 and, prior to becoming Chief Investment Officer in 2005, served as head of its Distressed Investment Group. From 1992 until 2001, he worked at Nomura Holdings America, where he served as Managing Director managing a team investing in a proprietary fund focused on distressed and other event-driven corporate investments. Mr. Embler currently serves, or during the preceding five years served, on the Board of Directors of Abovenet Inc., Corlears School and Kindred Healthcare Inc. He is an Independent Director at American Airlines Group Inc since 2013. |
| Mr Vincent Intrieri
| Effective May 7, 2012, Vincent J. Intrieri was appointed to the Board. |
| Mr Franz Humer
| Dr Franz B Humer is Chairman of Diageo plc in July 2008, having been a Non-Executive Director since April 2005. He is also Chairman of F. Hoffmann-La Roche Ltd in Switzerland, Chairman of INSEAD's Board of Directors and a Non-Executive Director of CitiGroup Inc. He was formerly Chief Operating Director of Glaxo Holdings plc and has held a number of other non-executive directorships. |
| Mr Anthony Santomero
| Anthony M. Santomero, Senior Advisor, McKinsey & Company - 2006 to 2008, President, Federal Reserve Bank of Philadelphia - 2000 to 2006, Richard K. Mellon Professor, Finance, The Wharton School at the University of Pennsylvania - 1984 to 2002, Director of Citigroup since 2009, Director of Citibank, N.A. since 2009 Other Directorships: RenaissanceRe Holdings, Ltd., Penn Mutual Life Insurance Company, Columbia Funds and B of A Fund Series Trust, Previous Directorships within the last five years: N/A, Other Activities: Drexel University (Trustee), Drexel University College of Medicine (Vice Chair and Trustee) and Ben Franklin Technology Partners of Southeast Pennsylvania (Director). Mr. Santomero will resign from B of A Fund Series Trust's Board as of June 30, 2011. |
| Mr Michael O'Neill
| Michael E. O'Neill, Chairman, Chief Executive Officer and Director, Bank of Hawaii Corporation - 2000 to 2004, Elected Chief Executive Officer, Barclay's PLC - 1999, Vice Chairman and Chief Financial Officer, Bank of America - 1995 to 1998, Chief Financial Officer, Continental Bank - 1993 to 1995, Director of Citigroup since 2009, Director of Citibank, N.A. since 2009, Other Directorships: FT Ventures (Advisory Board), Previous Directorships within the last five years: N/A, Other Activities: Hawaii Pacific University (Trustee) and Honolulu Academy of Arts (Trustee). The Board, consistent with its pre-existing succession planning, intends to select Michael E. O’Neill to succeed Mr. Parsons as Chairman following the stockholder meeting scheduled for April 17, 2012. |
| Mr Michael Corbat
| Michael L. Corbat is Chief Executive Officer of Citigroup, the world's global bank, with approximately 200 million customer accounts and activities in more than 160 countries and jurisdictions. Mr. Corbat has been at Citi and its predecessor companies since his graduation from Harvard University with a bachelor's degree in economics in 1983. In his previous role as Citi's CEO of Europe, Middle East and Africa since the start of 2012, he oversaw all of Citi's business operations in the region, including consumer banking, corporate and investment banking, securities and trading and private banking services. Previously, Mr. Corbat served as the CEO of Citi Holdings, Citi's portfolio of non-core businesses and assets. In this role, he oversaw the divestiture of more than 40 businesses, including the IPO and sale of Citi's remaining stake in Primerica. Mr. Corbat also successfully restructured Citi's consumer finance and retail partner cards businesses and divested more than $500 billion assets, reducing risk on the Company's balance sheet and freeing up capital to invest in Citi's core banking business. |
| Mr William Thompson
| William S. Thompson, Jr., Chief Executive Officer, PIMCO - 1993 to 2009, Salomon Brothers Inc. - 1975 to 1993, Chairman, Salomon Brothers Asia Ltd - 1991 to 1993, Head of Corporate Finance, Western Region - 1988 to 1991, Managing Director and Head of Institutional Sales, Western Region - 1981-1988, Joined Salomon Brothers – 1975, Director of Citigroup since 2009, Other Directorships: Pacific Life Corporation, Previous Directorships within the last five years: N/A, Other Activities: Pacific Symphony Orchestra (Director), Thompson Foundation for Autism (Chair), Thompson Family Foundation (President) and University of Missouri (President's Financial Advisory Council). |
| Ms Judith Rodin
| Dr. Judith Rodin, 70, is President of the Rockefeller Foundation. From 1994 to 2004, Dr. Rodin served as President of the University of Pennsylvania, as well as a professor of psychology and of medicine and psychiatry at the University of Pennsylvania. She also serves as a director of AMR Corporation and Citigroup Inc , She is a Director at Comcast Since Nov 2002. |
| Mr Nelson J. Chai
| Mr Nelson J. Chai served as Executive Vice President, Chief Administrative Officer and Head of Strategy from June 2010 to August 2011 at CIT. Prior to joining CIT, Mr. Chai served as President Asia-Pacific for Bank of America Inc. from December 2008 to February 2009, as a result of the merger between Bank of America Inc. and Merrill Lynch & Co., Inc. From December 2007 to December 2008, Mr. Chai was Executive Vice President and Chief Financial Officer of Merrill Lynch & Co., Inc. From January 2006 to December 2007, Mr. Chai was Executive Vice President and Chief Financial Officer of NYSE Euronext and its predecessor company NYSE Group, Inc. and, from 2005, he was Chief Financial Officer of Archipelago Holdings, a predecessor to NYSE Group, Inc., where he was responsible for Finance, Strategy, Human Resources, and Marketing functions since first joining Archipelago in June 2000. Mr. Chai serves as a director of Thermo Fisher Scientific since December 2010, serving on its audit and nominating & governance committees, and a director for the US Fund for UNICEF since 2005, serving as chair of its finance committee and a member of its executive committee. |
| Ms Judy C. Lewent
| Ms Judy C. Lewent is a board member at GlaxoSmithKline PLC. Ms. Judy Lewent Appointed on 1 April 2011. Judy served as Executive Vice President and Chief Financial Officer of Merck & Co., Inc. until September 2007. She is also a director of Thermo Fisher Scientific Inc since May 2008 and Motorola Solutions, Inc. She served on the boards of Motorola Inc. from 1995 until May 2010 and Dell Inc. from 2001 to 2011. She previously served on the board of Quaker Oats Company. Since 2009, Judy has served on the boards of Purdue Pharma Inc., Napp Pharmaceutical Holdings Limited and certain Mundipharma International Limited companies as a Non-Executive Director. She is also a Trustee and the Chairperson of the Audit Committee of the Rockefeller Family Trust, a life member of the Massachusetts Institute of Technology Corporation and a member of the American Academy of Arts & Sciences.Judy is a Non-Executive Director of Motorola Solutions Inc. She is also a Trustee and Chairperson of the Audit Committee of the Rockefeller Family Trust, a life member of the Massachusetts Institute of Technology Corporation and a member of the American Academy of Arts and Sciences.Judy served as Executive Vice President and Chief Financial Officer of Merck & Co., Inc. until September 2007. She also served as Chief Financial Officer starting in 1990 and held various other financial and management positions after joining Merck in 1980. She served on the Boards of Motorola Inc. from 1995 until May 2010 and Dell Inc. from 2001 to 2011 as well as previously serving on the Board of Quaker Oats Company. Judy has served as a Non-Executive Director on the Boards of Purdue Pharma Inc., Napp Pharmaceutical Holdings Limited and certain Mundipharma International Limited companies from 2009 to 2014. |
| Mr Tyler Jacks
| Dr Tyler Jacks, PhD was first identified to the Governance and Nominating Committee as a potential director candidate by Dr. David Baltimore, a member of the Company’s Board. Dr Jacks joined the Massachusetts Institute of Technology in 1992 and is currently the David H. Koch Professor of Biology and director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer. Dr. Jacks has been an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, since 2002. Dr. Jacks has been a director of Thermo Fisher Scientific, Inc since May 2009, a life sciences supply company, since May 2009 and was a founder of T2 Biosystems, Inc., a privately-held biotechnology company, since 2006. Dr. Jacks serves on numerous scientific advisory boards including Epizyme, Inc., a privately-held biopharmaceutical company, since 2007 and Aveo Pharmaceuticals Inc., a cancer therapeutics company, since 2001. Dr. Jacks was appointed to the National Cancer Advisory Board, which advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, in October 2011. Dr. Jacks was a director of the Massachusetts Institute of Technology’s Center for Cancer Research from 2001 to 2008 and received numerous awards including the Paul Marks Prize for Cancer Research and the American Association for Cancer Research Award for Outstanding Achievement. He was elected to the National Academy of Sciences as well as the Institute of Medicine in 2009. |
| Mr Marc N. Casper
| Mr Marc N. Casper is a Director, President and Chief Executive Officer of Thermo Fisher Scientific Inc. (“Thermo Fisher”) since October 2009. Mr Casper served as Executive Vice President and Chief Operating Officer of Thermo Fisher from May 2008 until he was named President and Chief Executive Officer. Following the merger of Thermo Electron Corporation and Fisher Scientific International Inc. in November 2006 until he was named Chief Operating Officer in May 2008, Mr Casper served as Executive Vice President of Thermo Fisher and President of its Analytical Technologies businesses. From December 2003 to November 2006, Mr Casper served as Senior Vice President of Thermo Electron Corporation. He earned an MBA with high distinction from Harvard Business School and received a B.A. in economics from Wesleyan University. Mr Casper is a director of Thermo Fisher and previously served as a director of The Advisory Board Company. Board Committees: Compensation and Management Development Committee and Corporate Governance Committee. |
| Mr Jim P. Manzi
| Mr Jim P. Manzi is the Chairman of the Board of Directors at Thermo Fisher Scientific Inc since May 2007 and a director of the Company since May 2000. He was also Chairman of the Board from January 2004 to November 2006. He has been the Chairman of Stonegate Capital, a firm he formed to manage private equity investment activities in technology startup ventures, primarily related to the Internet, since 1995. From 1984 until 1995, he served as the Chairman, President and Chief Executive Officer of Lotus Development Corporation, a software manufacturer that was acquired by IBM Corporation in 1995. We believe that Mr Manzi is well suited to serve on our Board due to his senior management experience leading Lotus and overall business acumen. |
| Ms Elaine S. Ullian
| Ms Elaine S. Ullian, From 1996 through January 2010 served as President and Chief Executive Officer of Boston Medical Center, a private, not-for-profit, 626-bed, academic medical center with a community-based focus. Ms Elaine S. Ullian is a member of board of directors at Thermo Fisher Scientific Inc since July 2001. From 1994 to 1996, she served as President and Chief Executive Officer of Boston University Medical Center Hospital. From 1987 to 1994, Ms. Ullian served as President and Chief Executive Officer of Faulkner Hospital. She also serves as a director of Thermo Fisher Scientific Inc. and Hologic, Inc. In addition, Ms. Ullian was a member of the Board of Directors of Valeant Pharmaceuticals, Inc. from 2005 through 2007. Ms. Ullian holds a B.A. in political science from Tufts University and an M.P.H. from the University of Michigan. |
| Mr Scott M. Sperling
| Mr Scott M. Sperling is a member of board of directors at Thermo Fisher Scientific Inc since November 2006. Prior to the merger of Thermo Electron Corporation and Fisher Scientific International Inc., he was a director of Fisher Scientific from January 1998 to November 2006. He has been employed by Thomas H. Lee Partners, L.P., a leveraged buyout firm, and its predecessor, Thomas H. Lee Company, since 1994. Mr Sperling currently serves as Co-President of Thomas H. Lee Partners, L.P. Mr Sperling is also a director of CC Media Holdings, Inc., and within the last five years was a director of Univision Communications Inc., Warner Music Group Corp. and Vertis, Inc. We believe that Mr Sperling is well suited to serve on our Board due to his experience in acquisitions and finance. |
| Mr Scott Donnelly
| Mr. Donnelly, 50, is Chairman, President and Chief Executive Officer of Textron. Mr. Donnelly joined Textron in June 2008 as Executive Vice President and Chief Operating Officer and was promoted to President and Chief Operating Officer in January 2009. He was appointed to the Board of Directors in October 2009, became Chief Executive Officer of Textron in December 2009 and Chairman of the Board in September 2010. Previously, Mr. Donnelly was the President and CEO of General Electric Company’s Aviation business unit, a position he had held since July 2005. GE’s Aviation business unit is a $16 billion maker of commercial and military jet engines and components as well as integrated digital, electric power and mechanical systems for aircraft. Prior to July 2005, Mr. Donnelly served as Senior Vice President of GE Global Research, one of the world’s largest and most diversified industrial research organizations with facilities in the U.S., India, China and Germany and held various other management positions since joining General Electric in 1989. He is a Director at Medtronic PLC since 2013. |
| Mr Patrick Yang
| Mr Patrick Yang has over 30 years of experience in manufacturing and technology. Currently, he is Head of Global Pharmaceutical Technical Operations for F. Hoffmann-La Roche Ltd., which operates in the pharmaceutical and diagnostics industry and sells products in more than 150 countries. Mr. Yang joined Roche in March 2009, upon Roche’s merger with Genentech, Inc., and is responsible for the company’s pharmaceutical manufacturing, process development, engineering, quality, regulatory, supply chain and procurement functions. Before joining Roche, Mr Yang served as Executive Vice President, Product Operations of Genentech, a biotechnology company, from December 2005 to March 2009 and in various other executive-level positions with Genentech from December 2003 to December 2005. Prior to joining Genentech, Mr. Yang worked for Merck & Co. from 1992 to 2003 in manufacturing and for General Electric from 1980 to 1992 in manufacturing and technology. Mr Patrick Yang is Independent Director of Tesoro Corp. |
| Mr Michael Wiley
| Mr Michael Wiley has served as a director since January 2005. Since 2005, Mr. Wiley has served as a director of Tesoro Corporation, a publicly traded independent oil refiner and marketer, and, since 2004, as a director of Post Oak Bank, NA, a privately held bank. Since 2007, Mr. Wiley has served as a Trustee of Fidelity Funds, equity and high-income mutual funds. Mr. Wiley served as Chairman of the Board and Chief Executive Officer of Baker Hughes Incorporated, a publicly traded oilfield services company, from August 2000 until October 2004. He also served as President of Baker Hughes Incorporated from August 2000 to February 2004. From 2001 until its sale in 2005, Mr. Wiley served as a director of Spinnaker Exploration Company, a publicly traded exploration and production company. Mr. Wiley was President and Chief Operating Officer of Atlantic Richfield Company, a publicly traded integrated energy company, from 1998 through May 2000. Prior to 1998, he served as Chairman, President, and Chief Executive Officer of Vastar Resources, Inc., a publicly traded exploration and production company. |
